PAVM Key Statistics, Chart & Performance
The current stock price of PAVM is 7.75 USD. In the past month the price increased by 17%. In the past year, price decreased by -61.09%.
PAVM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PAVM. When comparing the yearly performance of all stocks, PAVM is a bad performer in the overall market: 94.65% of all stocks are doing better.
PAVM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PAVM. PAVM has a bad profitability rating. Also its financial health evaluation is rather negative.
PAVM Financial Highlights
Over the last trailing twelve months PAVM reported a non-GAAP Earnings per Share(EPS) of -20.41. The EPS decreased by -388.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.56% | ||
| ROE | -1.66% | ||
| Debt/Equity | 0.19 |
PAVM Forecast & Estimates
8 analysts have analysed PAVM and the average price target is 321.3 USD. This implies a price increase of 4045.81% is expected in the next year compared to the current price of 7.75.
For the next year, analysts expect an EPS growth of -76.54% and a revenue growth -97.58% for PAVM
PAVM Ownership
PAVM Latest News, Press Relases and Analysis
About PAVM
Company Profile
PAVmed Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The company went IPO on 2016-07-27. PAVmed Inc. is a multi-product, commercial-stage medical technology company. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Company Info
PAVMED INC
360 Madison Avenue, 25th Floor
New York City NEW YORK 10165 US
CEO: Lishan Aklog
Employees: 39
Phone: 12129494319
PAVMED INC / PAVM FAQ
What does PAVM do?
PAVmed Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The company went IPO on 2016-07-27. PAVmed Inc. is a multi-product, commercial-stage medical technology company. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
What is the stock price of PAVMED INC today?
The current stock price of PAVM is 7.75 USD. The price increased by 1.44% in the last trading session.
What is the dividend status of PAVMED INC?
PAVM does not pay a dividend.
What is the ChartMill rating of PAVMED INC stock?
PAVM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting PAVM stock to perform?
8 analysts have analysed PAVM and the average price target is 321.3 USD. This implies a price increase of 4045.81% is expected in the next year compared to the current price of 7.75.
How many employees does PAVMED INC have?
PAVMED INC (PAVM) currently has 39 employees.
Who owns PAVMED INC?
You can find the ownership structure of PAVMED INC (PAVM) on the Ownership tab.